Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com
Equities research analysts at StockNews.com began coverage on shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) in a note issued to investors on Saturday. The firm set a "hold" rating on the stock.
StockNews.com的股票研究分析師在週六向投資者發佈的報告中開始報道Fresenius Medical Care AG&Co.KGaA(紐約證券交易所代碼:FMS-GET Rating)的股票。該公司對該股設定了“持有”評級。
FMS has been the topic of several other reports. DZ Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a research report on Friday, July 29th. JPMorgan Chase & Co. cut their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. Truist Financial lowered their price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating on the stock in a research note on Wednesday, June 22nd. Berenberg Bank lowered their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a research note on Wednesday, August 10th. Finally, Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from an "underperform" rating to a "buy" rating and lifted their target price for the stock from $30.30 to $33.70 in a report on Monday, June 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has a consensus rating of "Hold" and a consensus target price of $45.83.
FMS一直是其他幾份報告的主題。DZ銀行在7月29日星期五的一份研究報告中將Fresenius Medical Care AG&Co.KGaA的股票評級從買入下調至持有。摩根大通(JPMorgan Chase&Co.)在8月1日週一的一份研究報告中將費森尤斯醫療保健公司(Fresenius Medical Care AG&Co.KGaA)的股票目標價從51.00歐元(52.04美元)下調至23.00歐元(23.47美元)。6月22日,Truist Financial在一份研究報告中將費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的股票目標價從34.00美元下調至27.00美元,並在一份研究報告中將該股的評級設定為持有。貝倫貝格銀行在8月10日星期三的一份研究報告中將Fresenius Medical Care AG&Co.KGaA的股票目標價從76.70歐元(78.27美元)下調至57.95歐元(59.13美元)。最後,在6月27日星期一的一份報告中,傑富瑞金融集團將費森尤斯醫療保健股份公司的股票評級從表現不佳上調至買入,並將該股的目標價從30.30美元上調至33.70美元。一位股票研究分析師將該股的評級定為賣出,8位分析師給出了持有評級,3位分析師給出了買入評級。根據MarketBeat.com的數據,Fresenius Medical Care AG&Co.KGaA的共識評級為持有,共識目標價為45.83美元。
Fresenius Medical Care AG & Co. KGaA Trading Down 4.4 %
費森尤斯醫療保健公司KGaA股價下跌4.4%
FMS opened at $14.39 on Friday. The stock has a market capitalization of $8.43 billion, a P/E ratio of 9.17, a P/E/G ratio of 0.77 and a beta of 1.03. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $14.16 and a 12 month high of $36.08. The firm's fifty day simple moving average is $18.35 and its 200 day simple moving average is $25.81. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47.
FMS上週五開盤報14.39美元。該股市值為84.3億美元,市盈率為9.17,市盈率為0.77,貝塔係數為1.03。費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的股價跌至14.16美元的12個月低點和36.08美元的12個月高點。該公司的50日簡單移動均線為18.35美元,200日簡單移動均線為25.81美元。該公司的流動比率為1.18,速動比率為0.85,債務權益比率為0.47。
Institutional Trading of Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG&Co.KGaA的機構交易
Fresenius Medical Care AG & Co. KGaA Company Profile
費森尤斯醫療保健股份公司簡介
(Get Rating)
(獲取評級)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Fresenius Medical Care AG&Co KGaA在德國、北美和國際上提供透析護理和相關的透析護理服務。它通過門診透析診所網絡提供透析治療以及相關的實驗室和診斷服務;材料、培訓和患者支持服務,包括臨牀監測、後續援助和安排將用品運送到患者住所;以及根據合同向美國醫院提供為住院的終末期腎病(ESRD)患者和急性腎功能衰竭患者提供的透析服務。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免費獲取StockNews.com關於Fresenius Medical Care AG&Co.KGaA(FMS)的研究報告。
- MarketBeat:回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性?
- 小盤股的裁員是樓市的晴雨表嗎?
- 需要關注的2只半導體類股走勢逆轉
- 好市多盈利後價格疲軟是買入的好時機嗎?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
接受Fresenius Medical Care AG&Co.KGaA Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Fresenius Medical Care AG&Co.KGaA和相關公司的最新新聞和分析師評級的每日簡要摘要。